What we do
It is our mission to unravel the molecular details of the working of cells in their normal function and the perturbed functioning in diseased cells. We help translate our knowledge and technologies to clinical practice.
Research
Our common goal is simple and easily described, but the road we take and focus points we have in our science are very diverse. Ranging from virus biology to genome editing, diabetes and oncogenic signaling, our scope of interest covers a wide area of life science.
Affiliated labs
We collaborate with some of the worlds leading institutes in all field of science. Some of the labs we affiliate with and their leaders that hold positions at our department are:
Prof. Hidde Ploegh appointed as Jon J. van Rood-scholar ( Harvard Medical School, United States of America)
Prof. Brenda Schulman appointed as LUF-Boerhaave Visiting Professor (Max-Planck Institute, Martinsried, Germany)
News
-
-
Cellular Life, Death and everything in between
-
THESIS DEFENSE FRAUKE LIEBELT
-
Wel of geen tuberculose? Triage TB!
-
Selas Bots wins Oncolytic Virus Conference poster award
-
Improving throughput of cryo-lamella milling
Cases
-
PEP-TALKS for LUMC Patients and Personnel
What is really going on at the LUMC labs and research departments?
read more -
Clinical Internships
CCB department initiated Clinical Internships to bridge the fundamental research with the clinical practice.
read more -
Neutralized, but not inactivated
Viruses have shown renewed promise in the treatment of cancer, after new research has shown they retain their cancer-killing ability even when injected into the bloodstream. It is believed that the human body’s normal immune response neutralizes viruses that are injected into the bloodstream to try to destroy tumors during oncolytic virus therapy. In a new study investigating reovirus, scientists found that cells in the blood can reactivate the virus as it travels to the tumor site, allowing it to retain its ability to destroy the cancer cells.
read more